6th Annual Pharma Marketing & Branding Excellence

Jacob Fleming Group25 - 26 January 2011, Milan, Italy.
Recently, behaviors of pharmaceutical marketing landscape, which includes health care providers, patients, and consumers are changing. Pharma companies are now favoring marketing through new media technologies like mobile-Web integration and online interactivity.

Following five successful annuals, Jacob Fleming Group invites you to the 6th Annual Pharma Marketing & Branding Excellence. Jacob Fleming Group has gathered worldwide Pharma marketing specialists who will share their knowledge with you. Hear them speak about the most powerful marketing strategies and network face-to-face.

At this conference, you will have the chance to meet true market leaders, top speakers and real experts from pharmaceutical industry. Do not miss the opportunity to gain new knowledge and join us at this event of the year.

Key speakers:

  • Senior Vice President, Global Marketing, Bayer Healthcare, Germany
  • Head of Marketing, Specialty Care Business Unit, Pfizer, Finland
  • Director Strategic Marketing, Member of the Executive Committee, Abbott, Switzerland
  • Head of Marketing Scandinavia, UCB, Norway
  • Associate Director, EMEA Marketing, Baxter, Switzerland
  • Vice President, Franchise & Global Marketing Operations, Sanofi Pasteur, France
  • Founder and managing director of Webicina.com, Author of Scienceroll.com, University of Debrecen Medical School and Health
  • Senior Marketing Director, Pfizer, UK
  • Executive Director, Global Marketing Excellence, Johnson & Johnson, UK

Key topics:

  • Case studies from top pharmaceutical companies on how to target the most interesting segments through different channels
  • Understand, how to utilize the potential of mobile marketing & achieve greater brand interactivity and immediate response metrics for your brands.
  • Real life case studies on how to expand “traditional” e-detailing beyond its current limitations
  • Working case studies on how to develop and effective social media strategy
  • Find out how to achieve branding excellence in highly competitive market place
  • Experiences of top pharmaceutical companies on how to overcome barriers for effective closed loop marketing
  • Case studies on how to built sustainable brand equity in a commoditized market
  • Real life case studies on how to successfully select the most suitable brands for e-communication

Who should attend:
Senior Vice presidents, Vice presidents, Senior Executives, Global Heads, Heads, International Directors, Senior Directors, Directors, Senior Managers, Managers of: Marketing & Sales, Marketing, Marketing excellence, CRM, e-Marketing, Branding, Communication, Business Unit Directors, Strategic Planning, Commercial operations, Strategic Marketing, Brand management, Product Directors, Key Accounts, Advertising, Market research, Business Intelligence.

For further information and registration, please visit:
http://www.jacobfleming.com/jacob-fleming-group/conferences/life-science/6th-annual-marketing-branding-excellence?partner=worldpharmanewsMB

About Jacob Fleming Group
Jacob Fleming Conferences are carefully designed to provide key strategic business information and the best networking opportunities for the participants. Our business to business conferences are highly interactive events with a limited number of delegates from specialized industry sectors. For each conference Jacob Fleming brings together selected senior level executives who become part of a premium community discussing the questions of the day and enjoying the value of a five star event.

Most Popular Now

GSK reaches agreement with Novartis to acquire ful…

GlaxoSmithKline plc (LSE/NYSE: GSK) today announces that it has reached an agreement with Novartis for the buyout of Novartis' 36.5% stake in their Consumer Healthcare Jo...

Canadian neuroscientists say daily ibuprofen can p…

A Vancouver-based research team led by Canada's most cited neuroscientist, Dr. Patrick McGeer, has successfully carried out studies suggesting that, if started early enou...

First proof a synthesized antibiotic is capable of…

A "game changing" new antibiotic which is capable of killing superbugs has been successfully synthesised and used to treat an infection for the first time - and could lea...

Merck partners with Medisafe to help improve medic…

Merck, a leading science and technology company, today announced a new collaboration with US-based Medisafe to help its cardiometabolic patients better manage medication ...

Phase III data in The Lancet show Novartis siponim…

Novartis today announced that the full results from the Phase III EXPAND study of oral, once-daily siponimod (BAF312) in secondary progressive multiple sclerosis (SPMS) w...

Taking a standard prostate cancer drug with food b…

By taking a high-cost drug with a low-fat meal - instead of on an empty stomach, as prescribed - prostate cancer patients could decrease their daily dose, prevent digesti...

North and south cooperation to combat tuberculosis

Tuberculosis can be cured and could be eradicated. For this to happen, however, patients have to receive the right treatment. Researchers at the Makerere University and t...

New immunotherapy for lung cancer shows promise of…

In a groundbreaking development, results from a recent clinical trial to treat lung cancer show that a novel immunotherapy combination is surprisingly effective at contro...

Boehringer Ingelheim and OSE Immunotherapeutics an…

Boehringer Ingelheim and OSE Immunotherapeutics, a biotechnology company focused on the development of innovative immunotherapies, have announced a collaboration and excl...

Personalized tumor vaccine shows promise in pilot …

A new type of cancer vaccine has yielded promising results in an initial clinical trial conducted at the Perelman School of Medicine at the University of Pennsylvania and...

Lokelma approved in the EU for the treatment of ad…

AstraZeneca today announced that the European Commission has granted marketing authorisation for Lokelma (formerly ZS-9, sodium zirconium cyclosilicate) for the treatment...

New targeted therapy schedule could keep melanoma …

Skin melanoma, a particularly insidious cancer, accounts for the vast majority skin cancer deaths and is one of the most common cancers in people under 30. Treatment for ...